Скачать или смотреть Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biotechnology company focused on the development of T-cell receptor (TCR)-based cell therapies targeting solid tumors. Its proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the targeting of intracellular cancer antigens, expanding the therapeutic landscape beyond surface markers.

The company’s lead product, TECELRA® (afamitresgene autoleucel), received accelerated FDA approval in August 2024 for synovial sarcoma, marking a critical milestone. Adaptimmune is pursuing label expansion into myxoid/round cell liposarcoma (MRCLS), with a rolling BLA submission planned for late 2025.

Another key candidate is lete-cel, expected to launch by 2026. In MRCLS trials, lete-cel showed a 43% overall response rate and 12.2 months median duration of response—encouraging results for this hard-to-treat cancer segment.

Financially, the company remains challenged. Q1 2025 revenue was $7.3 million, primarily from TECELRA® sales. However, net loss reached $47.6 million, and cash reserves stood at $41.1 million, with total liquidity of $59.6 million. Management has expressed substantial doubt about the company’s ability to continue as a going concern and is exploring cost-saving measures and strategic options.

Market performance has been weak, with the share price down over 70% year-to-date, reflecting investor concerns over sustainability and commercial execution.

In summary, Adaptimmune is a scientifically advanced player in TCR therapy with first-mover advantage in solid tumors. Yet, financial strain and limited commercial traction present near-term risks. Future success hinges on TECELRA® uptake, expanded indications, and potential partnerships or acquisitions.